Alkem shares fall 3% after Q2 results; MOFSL retains Neutral rating
MOFSL said that FY27 is the year of consolidation for Alkem, as the new business is facing a gestation period before scale-up, with operational cost front-loaded and revenue yet to pick up
)
Alkem shares fall 3% after Q2 results; MOFSL retains Neutral rating
Listen to This Article
Shares of Alkem Laboratories fell over 3 per cent in intraday trade on Friday after the company reported its Q2FY27 results. MOFSL retained its ‘Neutral’ rating on the stock, citing FY27 as the year of consolidation for the company.
The company's counter at 11:17 AM was trading 2.05 per cent lower at ₹5,194 per share on NSE. In comparison, Nifty 50 was down 0.5 per cent at 25,170.40. In intraday trade, the stock fell 3.05 per cent to touch the day's low at ₹5,140 per share.
Alkem Laboratories Q2FY27 result
Alkem Laboratories reported a 13.8 per cent year-on-year (Y-o-Y) rise in revenue to ₹4,550 crore in Q2FY27, while earnings before interest, tax, depreciation and amortisation increased 11.3 per cent to ₹1,020 crore. Adjusted net profit, however, declined 14.8 per cent to ₹650 crore, partly due to higher depreciation and a high tax rate. It included an exceptional gain of ₹35 crore related to recovery against an impaired investment.
The company's domestic formulation business grew 9.5 per cent Y-o-Y to ₹3,030 crore, accounting for 67 per cent of revenue. International business revenue rose 22.3 per cent to ₹1,450 crore. Within this, US sales increased 2.4 per cent to ₹780 crore, while sales from other international markets grew 58.2 per cent to ₹670 crore, supported by stronger execution in Latin America.
Also Read
MOFSL on Alkem Laboratories
The brokerage noted that Alkem Laboratories delivered marginally better-than-expected revenue and Ebitda in 2QFY27. Better-than-expected performance in the international segment (largely non-US) was partly offset by subdued performance in trade generics within the India business and lower biotech sales for the quarter. “2Q earnings was marginally lower-than expected due to higher depreciation and a high tax rate for the quarter,” it added.
MOFSL added that FY27 is the year of consolidation for Alkem, as the new business is facing a gestation period before scale-up, with operational cost front-loaded and revenue yet to pick up. Regulatory issues at Daman have also dragged down the overall financial performance.
“With the scale-up of biotech and med-tech business and improved operating leverage in India business, we expect earnings growth to revive in FY28E. Maintain Neutral with a target price of ₹5,890,” the brokerage said.
Disclaimer: Views and outlook in this report belong to the brokerages and analysts cited. They do not reflect the views of Business Standard. Readers are advised to exercise discretion.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Nov 13 2026 | 11:28 AM IST
